Gilead picks Amazon as cloud provider for new medicines development

01 December 2021 | News

Gilead will use AWS machine learning and analytics to better inform clinical trial design and advance data-driven decision making

US-based Gilead Sciences has selected Amazon Web Services (AWS) as its preferred cloud provider. Innovating on AWS and with the help of AWS experts and partners in healthcare and life sciences, Gilead provides its data scientists with the latest advances in machine learning and analytics.

The capabilities fuel data-driven decision making across the organisation—from biomarker discovery through manufacturing and clinical trial recruitment—and deliver insights that can help Gilead refine its drug pipeline.

The company also relies on AWS to host all workloads for its enterprise resource planning (ERP) transformation project to implement SAP S/4HANA.

The use of AWS's compute, machine learning, and database capabilities will support the analysis and integration of diverse genomics, imaging, and experimental datasets to support breakthroughs in how Gilead diagnoses and treats diseases.

This is Gilead's first implementation of production-scale ERP systems in the cloud, and AWS provides the company's IT transformation team with scalable, secure, and high-performing infrastructure.

The company also plans to migrate hundreds of applications to AWS, which include critical applications that support industry good practices (GxP) guidelines and regulations in areas like drug manufacturing, storage, and distribution.